UNIVERSITÉ PARIS DESCARTES

**Faculté de Médecine**
**Site Cochin**

Prof. Isabelle FAJAC
Laboratoire de Physiologie Respiratoire
UPRES EA 2511
Mucoviscidose et bronchopathies chroniques: biopathologie et phénotypes cliniques
Faculté de Médecine, Site Cochin
24 rue du Faubourg St Jacques
75014 PARIS
FRANCE
Tel : +33 1 44 41 23 30
Fax : +33 1 44 41 23 33
Email : isabelle.fajac@parisdescartes.fr

Paris, 30 March 2017

Dear ECFS Members,

I hereby would like to apply to be the next ECFS President as from June 2018.

I am a Pulmonologist by training and I have a position as Professor in Physiology. I have worked on CF for the last 25 years: first I worked in the clinics following adult patients, then I worked full-time in a lab on gene therapy for CF. I then came back to the clinics and I currently work at the adult CF centre, in the Physiology Department of Cochin Hospital in Paris, France. I am involved in functional assessment of CFTR for the diagnosis of CFTR-related diseases and in pulmonary function tests. There is a Clinical Trial Unit in our Department and I also work a lot in CF clinical research.

I have been working on ECFS projects since 2008 when the ECFS-CTN was launched. I was a member of its Executive Committee and then I had the great honour of being its Director from 2012 to 2014. I also participate in other ECFS work and committees such as the ECFS Board, the Scientific Committee of the ECFS Conference and the Editorial Board of the Journal of Cystic Fibrosis.

Thanks to the previous Presidents, the Board members, the Executive Director and indeed all ECFS members, the ECFS has become a major stakeholder in CF with great projects and achievements in terms of care: the regularly updated standards of care and the consensus statements are a reference to us all; in terms of research: the working groups develop projects and publish their results, and the ECFS-CTN has helped to bring new medication faster to the patient; in terms of understanding the disease: the European CF Registry is a major source of knowledge on the disease; in terms of communication and knowledge dissemination: the two European conferences and the Journal of Cystic Fibrosis are success stories.

If I am elected, I would like to work with the Board members to continue to strengthen and expand these projects. Indeed, these ongoing projects are critical as CF disease is changing with more CF patients with a better life expectancy and new medication that should ultimately be available to all patients regardless of genotype or country. A new project on Education has just been launched to help us all from students to care givers, to researchers, to stay current and to train new care givers and researchers on CF. It is a very important

project aligned with ECFS' missions and it will need fostering and support in the coming years to become a major asset of our Society. I think we also need to strengthen science and translational research and if the ECFS Board agrees, we could work on a new project aiming at fostering CF research on top priority topics at a European level. It could attract young and talented researchers across Europe, help bridge care givers and researchers, and allow fruitful discussions and collaborations with Patients' Organisations.

I am convinced that for a rare disease like CF, it is of the utmost importance to overcome our national boundaries and specific ways of thinking to work across the borders, share our goals and visions and thus, build and implement coordinated and powerful projects. ECFS is the wonderful international community where such goals can be defined, worked on and come true. If I have the honour of being elected, I will work with the other ECFS Board members and all of you to further develop our Society, strengthen its work in CF care, education and research and build new initiatives fit to the changing CF world.

Kind regards,



Isabelle FAJAC